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Background: Anti-apoptotic BCL-2 family members antagonise apoptosis by sequestering their pro-apoptotic counterparts. The
balance between the different BCL-2 family members forms the basis of BH3 profiling, a peptide-based technique used to predict
chemosensitivity of cancer cells. Recent identification of cell-permeable, selective inhibitors of BCL-2, BCL-XL and MCL-1, further
facilitates the determination of the BCL-2 family dependency of cancer cells.
Methods: We use BH3 profiling in combination with cell death analyses using a chemical inhibitor toolkit to assess
chemosensitivity of cancer cells.
Results: Both BH3 profiling and the inhibitor toolkit effectively predict chemosensitivity of cells addicted to a single anti-apoptotic
protein but a combination of both techniques is more instructive when cell survival depends on more than one anti-apoptotic protein.
Conclusions: The inhibitor toolkit provides a rapid, inexpensive and simple means to assess the chemosensitivity of tumour cells
and in conjunction with BH3 profiling offers much potential in personalising cancer therapy.
A cardinal feature of cancer cells is their resistance to apoptosis.
Cancer chemotherapeutic drugs induce apoptosis primarily by
perturbation of mitochondrial integrity, which is regulated by the
BCL-2 family of proteins. Anti-apoptotic BCL-2 family proteins,
principally BCL-2, BCL-XL and MCL-1, maintain survival of
cancer cells by sequestering their pro-apoptotic counterparts.
Although the literature abounds with many purported BCL-2
family inhibitors, few are specific (Vogler et al, 2009b; Varadarajan
et al, 2013). Two specific inhibitors, navitoclax (ABT-263), which
inhibits BCL-2, BCL-XL and BCL-w, and venetoclax (ABT-199),
which inhibits BCL-2, have recently entered clinical trials (Tse
et al, 2008; Souers et al, 2013) and show promise in haematological
malignancies, such as chronic lymphocytic leukaemia (CLL)
(Roberts et al, 2015). Recently, A-1331852 and A-1210477 have
been identified as specific inhibitors of BCL-XL and MCL-1,
respectively (Leverson et al, 2015a, b). Importantly ABT-199,
A-1331852 and A-1210477, are cell-permeable, thus permitting
direct interrogation of cancer cells to ascertain the key proteins
responsible for their survival.
BH3 profiling is a peptide-based technique used to predict the
chemosensitivity of cancer cells and measures the ability of
different BH3 peptides to induce mitochondrial depolarisation,
which acts as a surrogate marker for the cellular response to
chemotherapeutic agents (Ni Chonghaile et al, 2011). Recently
Letai and co-workers established a related, dynamic BH3 profiling
(DBP) to measure early changes in pro-apoptotic signalling
following exposure to chemotherapeutic agents (Montero et al,
2015). In this communication, we compare BH3 profiling with a
chemical toolkit comprising specific BCL-2 family inhibitors
and assess additional benefits of employing them together to
address chemoresistance and BCL-2 family dependence of various
cancer cells.
MATERIALS AND METHODS
Cell culture. Peripheral blood samples from CLL patients were
obtained with patient consent and local ethics committee approval
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and cultured as described (Vogler et al, 2009b). MOLT-4 and
H1299, an AML and non-small cell lung carcinoma cell line,
respectively, were cultured in RPMI 1640 medium supplemented
with 10% foetal calf serum and 5mM L-glutamine (Life Technologies
Inc., Paisley, UK). H929, a multiple myeloma cell line, was cultured
in the same medium supplemented with 0.02% 2-mercaptoethanol.
All cell lines were from ATCC (Middlesex, UK).
Reagents. ABT-199, A-1331852 and A-1210477 were kindly
supplied by Abbvie Inc., (North Chicago, IL, USA). Peptides for
BIM (MRPEIWIAQELRR IGDEFNA), BAD (LWAAQRYGRELR
RMSDEFEGSFKGL), MS-1 (RPEIWMTQGLRRLGDEINAYYAR),
HRK (WSSAAQLTAARLKALGDELHQ) and PUMA-2A (EQW
AREIGAQARRMAADLNA) were from New England Peptide
(Gardner, MA, USA) or GenScript (Piscataway, NJ, USA).
Other reagents were from Sigma-Aldrich Co. (St. Louis, MO,
USA).
BH3 profiling, DBP and apoptosis. For BH3 profiling, cells were
permeabilised with digitonin (0.002%) and loss of mitochondrial
membrane potential (cm) assessed using TMRE (200 nM) after
incubation with BH3 peptides as described (Ryan and Letai, 2013).
For DBP, cells were incubated for 1 h with A-1331852 (1 mM),
A-1210477 (10 mM) or ABT-199 (1 mM) prior to incubation with
BAD or MS-1 peptide (10 mM) for 2 h and assessment of cm.
Apoptosis was quantified by measuring phosphatidylserine exter-
nalisation (Vogler et al, 2009b).
RESULTS
To validate the efficacy of BH3 profiling on cells addicted to
specific BCL-2 family members, primary CLL cells, addicted to
BCL-2 (Del Gaizo Moore et al, 2007; Vogler et al, 2009a, b),
MOLT-4 and H929 cell lines, addicted to BCL-XL (Leverson et al,
2015a) and MCL-1 (Leverson et al, 2015b), respectively, and
H1299 cells addicted to both BCL-XL and MCL-1 (Varadarajan
et al, 2013) were selected. For initial BH3 profiling experiments,
BIM was used as a positive control due to its ability to interact with
all anti-apoptotic members and PUMA-2A was a negative control.
HRK and MS-1 peptides react exclusively with BCL-XL and
MCL-1, respectively, and BAD peptide reacts with BCL-2, BCL-XL
and BCL-w (Ryan and Letai, 2013; Foight et al, 2014). BH3 profiling
showed that all the cells were primed for mitochondrial-dependent
cell death by their sensitivity to BIM peptide. Chronic lymphocytic
leukaemia cells were sensitive to BIM and BAD peptides but not to
HRK or MS-1, consistent with their BCL-2-addiction. However, as
the BAD peptide was much less efficient than the BIM peptide, it
suggested that CLL cells may depend on additional BCL-2 family
proteins for survival in scenarios, such as an alteration in tissue
microenvironment (Vogler et al, 2009a). Some support for this was
provided by the increased mitochondrial depolarisation observed
following combination of BAD and MS-1 peptides (Figure 1B).
However, the CLL cells used in this study from four different
patients predominantly expressed BCL-2 with little or no BCL-XL
or MCL-1 (Figure 1C). In contrast, MOLT-4 cells exhibited
sensitivity to BIM, BAD and HRK but not MS-1, suggesting their
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Figure 1. BH3 profiling in cell lines. (A) Cells were incubated with BH3 peptides (10 mM) in TEB buffer (containing 0.002% digitonin) for CLL cells
(30min), MOLT-4 cells (1 h), and H929 and H1299 cells (2 h). Mitochondrial potential was assessed and changes calculated with reference to DMSO
& FCCP-treated cells. Data represents the Mean±s.e.m. of triplicate experiments. (B) Mitochondrial depolarisation of CLL cells exposed to BAD
and MS-1 peptides alone or in combination. (C) Western blots of either CLL cells from four patients or the cell lines were analysed for expression of
the indicated proteins. No detectable BCL-w or BFL-1 was observed in any of the cells.
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dependence on BCL-XL and not MCL-1 for survival (Figure 1A).
BH3 profiling of H929 cells revealed sensitivity to BIM and MS-1
peptides, in agreement with their reported addiction to MCL-1,
although some sensitivity to BAD was also observed (Figure 1A).
Only BIM induced significant mitochondrial depolarisation in
H1299 cells (Figure 1A), suggesting that H1299 cells depended on
more than one BCL-2 family member for survival. What regulates
the dependency of these cell types on a specific BCL-2 family
member is still unknown, as in addition to expressing the expected
anti-apoptotic member required for their survival, namely BCL-2
for CLL, BCL-XL for MOLT-4 and MCL-1 for H929, other anti-
apoptotic proteins were also expressed (Figure 1C) in agreement
with earlier studies (Del Gaizo Moore et al, 2007, 2008).
BH3 profiling offers insight into the BCL-2 family dependency
of cancer cells and has been particularly valuable, while a limited
range of selective potent BCL-2 family inhibitors was available.
However, since the recent discovery of specific inhibitors of BCL-
XL and MCL-1, we questioned if the inhibitor toolkit comprising
ABT-199, A-1331852 and A-1210477 (targeting BCL-2, BCL-XL
and MCL-1, respectively) might be sufficient to draw similar
conclusions. To accomplish this, apoptosis was assessed in
response to these inhibitors. Chronic lymphocytic leukaemia cells
were exquisitely sensitive to ABT-199 (IC50¼ 2.5 nM after 4-h
exposure) but insensitive to A-1210477 and to a great extent to
A-1331852 (IC50¼ 1.1mM) (Figure 2), thus confirming that CLL
cells are addicted to BCL-2. MOLT-4 cells were sensitive only to
A-1331852 (IC50 B6.7 nM), supporting their dependence on BCL-
XL, whereas H929 were only sensitive to A-1210477 (IC50¼
1.8mM), confirming their MCL-1 addiction (Figure 2). In
agreement with BH3 profiling, H1299 cells were insensitive to all
three inhibitors alone (Figure 2), suggesting a possible dependence
on more than one anti-apoptotic BCL-2 family member.
To assess if multiple BCL-2 family members regulated apoptosis
in H1299 cells, we carried out DBP following exposure of cells to
the specific inhibitors for 1 h prior to BH3 profiling with BAD or
MS-1 peptide. In H1299 cells, exposure to A-1210477 but not
ABT-199 or A-1331852 increased sensitivity to BAD, confirming a
dependency on MCL-1 and either BCL-2 and/or BCL-XL for
survival (Figure 3A). To distinguish between BCL-2 and BCL-XL,
we carried out similar treatments with the inhibitors but profiled
using MS-1. Prior exposure to A-1331852 but not ABT-199 or
A-1210477 sensitised cells to MS-1 (Figure 3A). Taken together,
these results suggested that H1299 cells depended on both MCL-1
and BCL-XL for survival, which was further confirmed by the
extensive apoptosis observed following a combination of
A-1331852 and A-1210477 (Figure 3B). Following inhibition of
MCL-1 in H1299 cells, the apparent IC50 for A-1331852 was
1.4 nM, which was similar to that observed in MOLT-4 cells.
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Figure 2. BH3-mimetic-induced apoptosis in (A) CLL, (B) MOLT-4, (C) H929 and (D) H1299 cells. Cells were incubated with ABT-199 (BCL-2
inhibitor), A-1331852 (BCL-XL inhibitor) and A-1210477 (MCL-1 inhibitor) for 4 h and apoptosis determined. Data represents the mean±s.e.m. of
triplicate experiments.
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Figure 3. Synergy in H1299 cells. H1299 cells (A) were incubated for 1 h
with ABT-199 (1 mM), A-1331852 (1mM) or A-1210477 (10mM) prior to
profiling with either BAD or MS-1 (10mM) peptide for 2 h and loss of cm
measured. (B) H1299 cells were coincubated with A-1210477 (10 mM)
and with A-1331852 for 4 h before apoptosis was measured. Data
represents the mean±s.e.m. of triplicate experiments.
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DISCUSSION
Assessment of mitochondrial perturbation in response to different
BH3 peptides, clearly provides valuable mechanistic insights into
mitochondrial alterations that affect apoptotic signalling, whereas the
cell-permeable chemical inhibitor toolkit gives a simple direct
readout of apoptosis from a simple cell culture system. Limitations
of BH3 profiling include some difficulty in choosing optimal peptide
concentrations, whereas current limitations of the inhibitor toolkit
include the lack of specific inhibitors for the less common anti-
apoptotic BCL-2 family members, such as BCL-2-A1 and BCL-w, as
well as the lower potency of the MCL-1 inhibitor compared with
those for BCL-2 and BCL-XL. Currently there are major efforts to
develop more specific and potent inhibitors of MCL-1, as MCL-1 is a
major resistance factor to ABT-263-induced apoptosis (van Delft
et al, 2006; Zhang et al, 2011; Gores and Kaufmann, 2012). In some
cases we observed conflicting results between BH3 profiling and the
inhibitor toolkit, for example, the BAD peptide induced mitochon-
drial depolarisation in H929 cells implying a possible BCL-2/BCL-XL
dependence (Figure 1A), whereas the inhibitor data indicated MCL-1
dependence of the cells (Figure 2), in agreement with other data in
the literature (Leverson et al, 2015b). Although the reason for this is
unclear, it may indicate a limitation of using 23mer peptides, which
can only partially mimic the endogenous protein. This together with
some promiscuity of the peptides indicates that the inhibitor toolkit
may ultimately be a more reliable predictor of tumour sensitivity
than BH3 profiling, although this requires further validation. From a
therapeutic perspective, it is most attractive to treat tumours with a
specific BCL-2 family inhibitor, as that will lessen the likelihood of
non-specific toxicities, although this may result in a more rapid
development of resistance. Thus both BH3 profiling and the selective
chemical inhibitor toolkit successfully identified cells dependent on a
single anti-apoptotic BCL-2 family member for survival (Figures 1
and 2). However, most cancer cells probably depend on more than
one anti-apoptotic protein for survival. In this regard, the DBP
experiments are instructive. A short exposure (1 h) to A-1331852 and
A-1210477 sensitised H1299 cells to MS-1 and BAD peptide,
respectively (Figure 3A). Besides clearly demonstrating the depen-
dency of H1299 cells on both BCL-XL and MCL-1 for survival, these
results illustrate how rapidly the inhibitors penetrate cells and inhibit
their target proteins. Our results highlight the ability of the inhibitor
toolkit to provide a rapid, inexpensive and simple means to assess the
chemosensitivity of tumour cells and in conjunction with DBP to
facilitate the optimisation of individualised therapy.
ACKNOWLEDGEMENTS
We thank NorthWest Cancer Research (NWCR) for financial support
(CR994) and Ms Jane Tinsley and Dr Mel Oates for CLL samples.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM,
explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117: 112–121.
Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A (2008) BCL-
2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
Blood 111: 2300–2309.
Foight GW, Ryan JA, Gulla´ SV, Letai A, Keating AE (2014) Designed BH3
peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS
Chem Biol 9: 1962–1968.
Gores GJ, Kaufmann SH (2012) Selectively targeting Mcl-1 for the treatment
of acute myelogenous leukemia and solid tumors. Genes Dev 26: 305–311.
Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont
LD, Nimmer P, Xiao Y, Ma XM, Lowes KN, Kovar P, Chen J, Jin S, Smith
M, Xue J, Zhang H, Oleksijew A, Magoc TJ, Vaidya KS, Albert DH,
Tarrant JM, La N, Wang L, Tao Z-F, Wendt MD, Sampath D, Rosenberg
SH, Tse C, Huang DCS, Fairbrother WJ, Elmore SW, Souers AJ (2015a)
Exploiting selective BCL-2 family inhibitors to dissect cell survival
dependencies and define improved strategies for cancer therapy. Sci Transl
Med 7: 279ra40.
Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, Nimmer P, Jin S,
Smith M, Xiao Y, Kovar P, Tanaka A, Bruncko M, Sheppard GS, Wang L,
Gierke S, Kategaya L, Anderson DJ, Wong C, Eastham-Anderson J, Ludlam
MJC, Sampath D, Fairbrother WJ, Wertz I, Rosenberg SH, Tse C, Elmore
SW, Souers AJ (2015b) Potent and selective small-molecule MCL-1
inhibitors demonstrate on-target cancer cell killing activity as single agents
and in combination with ABT-263 (navitoclax). Cell Death Dis 6: e1590.
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H,
Horowitz NS, Berkowitz RS, Matulonis U, Janne PA, Amrein PC, Cichowski
K, Drapkin R, Letai A (2015) Drug-induced death signaling strategy rapidly
predicts cancer response to chemotherapy. Cell 160: 977–989.
Ni Chonghaile T, Sarosiek KA, Vo T-T, Ryan JA, Tammareddi A, Moore
VDG, Deng J, Anderson KC, Richardson P, Tai Y-T, Mitsiades CS,
Matulonis UA, Drapkin R, Stone R, DeAngelo DJ, McConkey DJ, Sallan
SE, Silverman L, Hirsch MS, Carrasco DR, Letai A (2011) Pretreatment
mitochondrial priming correlates with clinical response to cytotoxic
chemotherapy. Science 334: 1129–1133.
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF,
Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu
M, Desai MB, Cerri E, Enschede SH, Humerickhouse RA, Wierda WG,
Seymour JF (2015) Targeting BCL2 with venetoclax in relapsed chronic
lymphocytic leukemia. N Engl J Med 374: 311–322.
Ryan J, Letai A (2013) BH3 profiling in whole cells by fluorimeter or FACS.
Methods 61: 156–164.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD,
Ding H, Enschede SH, Fairbrother WJ, Huang DCS, Hymowitz SG, Jin S,
Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD,
Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park C-M, Phillips DC,
Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse
C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH,
Elmore SW (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves
antitumor activity while sparing platelets. Nat Med 19: 202–208.
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF,
Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X,
Zhang H, Fesik S, Rosenberg SH, Elmore SW (2008) ABT-263: a potent
and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421–3428.
van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE,
Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DCS
(2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and
efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer
Cell 10: 389–399.
Varadarajan S, Vogler M, Butterworth M, Dinsdale D, Walensky LD, Cohen
GM (2013) Evaluation and critical assessment of putative MCL-1
inhibitors. Cell Death Differ 20: 1475–1484.
Vogler M, Butterworth M, Majid A, Walewska RJ, Sun X-M, Dyer MJS, Cohen
GM (2009a) Concurrent up-regulation of BCL-XL and BCL2A1 induces
approximately 1000-fold resistance to ABT-737 in chronic lymphocytic
leukemia. Blood 113: 4403–4413.
Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJS,
Cohen GM (2009b) Different forms of cell death induced by putative
BCL2 inhibitors. Cell Death Differ 16: 1030–1039.
Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW,
Leverson JD, Lam LT (2011) Mcl-1 is critical for survival in a subgroup of
non-small-cell lung cancer cell lines. Oncogene 30: 1963–1968.
This work is licensed under the Creative Commons
Attribution 4.0 International License. To view a copy
of this license, visit http://creativecommons.org/licenses/by/4.0/
Predicting cancer cell sensitivity BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.49 641
